Biome Australia Limited (ASX: BIO) delivered a strong FY26 performance, supported by record sales growth, expanding market presence and improved financial strength. The company achieved annual sales revenue of AU$23.9 million, reflecting a 30% increase compared with the previous year, driven by continued demand for its Activated Probiotics and Activated Therapeutics product ranges. Biome Daily secured the leading position among probiotic products in Australian pharmacies, highlighting strong consumer adoption and brand momentum. The company also advanced its long-term growth strategy through an onshore manufacturing partnership and further development of its proprietary BMB18 probiotic strain through patent progress and clinical trials. Financial performance strengthened with positive operating cash flow, higher cash reserves and reduced debt levels, providing greater flexibility to support future expansion, innovation and commercial growth.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Biome Australia Achieves Record FY26 Performance
Biome Australia Limited (ASX: BIO) delivered a strong FY26 performance, supported by record sales growth, expanding market presence and improved financial strength. The company achieved annual sales revenue of AU$23.9 million, reflecting a 30% increase compared with the previous year, driven by continued demand for its Activated Probiotics and Activated Therapeutics product ranges. Biome Daily secured the leading position among probiotic products in Australian pharmacies, highlighting strong consumer adoption and brand momentum. The company also advanced its long-term growth strategy through an onshore manufacturing partnership and further development of its proprietary BMB18 probiotic strain through patent progress and clinical trials. Financial performance strengthened with positive operating cash flow, higher cash reserves and reduced debt levels, providing greater flexibility to support future expansion, innovation and commercial growth.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au